Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY

Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1,

Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer

HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6

HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.

IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual